378 related articles for article (PubMed ID: 26977881)
1. A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity.
Jing H; Hu J; He B; Negrón Abril YL; Stupinski J; Weiser K; Carbonaro M; Chiang YL; Southard T; Giannakakou P; Weiss RS; Lin H
Cancer Cell; 2016 Mar; 29(3):297-310. PubMed ID: 26977881
[TBL] [Abstract][Full Text] [Related]
2. The histone deacetylase SIRT2 stabilizes Myc oncoproteins.
Liu PY; Xu N; Malyukova A; Scarlett CJ; Sun YT; Zhang XD; Ling D; Su SP; Nelson C; Chang DK; Koach J; Tee AE; Haber M; Norris MD; Toon C; Rooman I; Xue C; Cheung BB; Kumar S; Marshall GM; Biankin AV; Liu T
Cell Death Differ; 2013 Mar; 20(3):503-14. PubMed ID: 23175188
[TBL] [Abstract][Full Text] [Related]
3. Direct Comparison of SIRT2 Inhibitors: Potency, Specificity, Activity-Dependent Inhibition, and On-Target Anticancer Activities.
Spiegelman NA; Price IR; Jing H; Wang M; Yang M; Cao J; Hong JY; Zhang X; Aramsangtienchai P; Sadhukhan S; Lin H
ChemMedChem; 2018 Sep; 13(18):1890-1894. PubMed ID: 30058233
[TBL] [Abstract][Full Text] [Related]
4. Identification of a Selective SIRT2 Inhibitor and Its Anti-breast Cancer Activity.
Shah AA; Ito A; Nakata A; Yoshida M
Biol Pharm Bull; 2016; 39(10):1739-1742. PubMed ID: 27725455
[TBL] [Abstract][Full Text] [Related]
5. A Small-Molecule SIRT2 Inhibitor That Promotes K-Ras4a Lysine Fatty-Acylation.
Spiegelman NA; Hong JY; Hu J; Jing H; Wang M; Price IR; Cao J; Yang M; Zhang X; Lin H
ChemMedChem; 2019 Apr; 14(7):744-748. PubMed ID: 30734528
[TBL] [Abstract][Full Text] [Related]
6. Selective SIRT2 inhibitors as promising anticancer therapeutics: An update from 2016 to 2020.
Roshdy E; Mustafa M; Shaltout AE; Radwan MO; Ibrahim MAA; Soliman ME; Fujita M; Otsuka M; Ali TFS
Eur J Med Chem; 2021 Nov; 224():113709. PubMed ID: 34303869
[TBL] [Abstract][Full Text] [Related]
7. Novel Lysine-Based Thioureas as Mechanism-Based Inhibitors of Sirtuin 2 (SIRT2) with Anticancer Activity in a Colorectal Cancer Murine Model.
Farooqi AS; Hong JY; Cao J; Lu X; Price IR; Zhao Q; Kosciuk T; Yang M; Bai JJ; Lin H
J Med Chem; 2019 Apr; 62(8):4131-4141. PubMed ID: 30986062
[TBL] [Abstract][Full Text] [Related]
8. Assessment of SIRT2 Inhibitors in Mouse Models of Cancer.
Negrón Abril YL; Fernández I; Weiss RS
Methods Mol Biol; 2019; 1983():151-171. PubMed ID: 31087297
[TBL] [Abstract][Full Text] [Related]
9. A Glycoconjugated SIRT2 Inhibitor with Aqueous Solubility Allows Structure-Based Design of SIRT2 Inhibitors.
Hong JY; Price IR; Bai JJ; Lin H
ACS Chem Biol; 2019 Aug; 14(8):1802-1810. PubMed ID: 31373792
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 2-((4,6-dimethylpyrimidin-2-yl)thio)-N-phenylacetamide derivatives as new potent and selective human sirtuin 2 inhibitors.
Yang L; Ma X; Yuan C; He Y; Li L; Fang S; Xia W; He T; Qian S; Xu Z; Li G; Wang Z
Eur J Med Chem; 2017 Jul; 134():230-241. PubMed ID: 28415012
[TBL] [Abstract][Full Text] [Related]
11. HaloTag-Targeted Sirtuin-Rearranging Ligand (SirReal) for the Development of Proteolysis-Targeting Chimeras (PROTACs) against the Lysine Deacetylase Sirtuin 2 (Sirt2)*.
Schiedel M; Lehotzky A; Szunyogh S; Oláh J; Hammelmann S; Wössner N; Robaa D; Einsle O; Sippl W; Ovádi J; Jung M
Chembiochem; 2020 Dec; 21(23):3371-3376. PubMed ID: 32672888
[TBL] [Abstract][Full Text] [Related]
12. Lessons learned from a SIRT2-selective inhibitor.
Jing H; Lin H
Oncotarget; 2016 Apr; 7(17):22971-2. PubMed ID: 27050282
[No Abstract] [Full Text] [Related]
13. AK-1, a SIRT2 inhibitor, destabilizes HIF-1α and diminishes its transcriptional activity during hypoxia.
Lee SD; Kim W; Jeong JW; Park JW; Kim JE
Cancer Lett; 2016 Apr; 373(1):138-145. PubMed ID: 26808575
[TBL] [Abstract][Full Text] [Related]
14. X-ray crystal structure guided discovery of new selective, substrate-mimicking sirtuin 2 inhibitors that exhibit activities against non-small cell lung cancer cells.
Yang LL; Wang HL; Zhong L; Yuan C; Liu SY; Yu ZJ; Liu S; Yan YH; Wu C; Wang Y; Wang Z; Yu Y; Chen Q; Li GB
Eur J Med Chem; 2018 Jul; 155():806-823. PubMed ID: 29957526
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Selective SIRT2 Inhibitors as Therapeutic Agents in B-Cell Lymphoma and Other Malignancies.
Chowdhury S; Sripathy S; Webster A; Park A; Lao U; Hsu JH; Loe T; Bedalov A; Simon JA
Molecules; 2020 Jan; 25(3):. PubMed ID: 31973227
[TBL] [Abstract][Full Text] [Related]
16. Structure activity study of S-trityl-cysteamine dimethylaminopyridine derivatives as SIRT2 inhibitors: Improvement of SIRT2 binding and inhibition.
Radwan MO; Ciftci HI; Ali TFS; Koga R; Tateishi H; Nakata A; Ito A; Yoshida M; Fujita M; Otsuka M
Bioorg Med Chem Lett; 2020 Oct; 30(19):127458. PubMed ID: 32755678
[TBL] [Abstract][Full Text] [Related]
17. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
[TBL] [Abstract][Full Text] [Related]
18. Novel c-Myc-Targeting Compound
Sriratanasak N; Petsri K; Laobuthee A; Wattanathana W; Vinayanuwattikun C; Luanpitpong S; Chanvorachote P
Mol Pharmacol; 2020 Aug; 98(2):130-142. PubMed ID: 32487733
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of SIRT2 suppresses hepatic fibrosis.
Arteaga M; Shang N; Ding X; Yong S; Cotler SJ; Denning MF; Shimamura T; Breslin P; Lüscher B; Qiu W
Am J Physiol Gastrointest Liver Physiol; 2016 Jun; 310(11):G1155-68. PubMed ID: 27125275
[TBL] [Abstract][Full Text] [Related]
20. Anti-proliferative effects of γ-tocotrienol are associated with suppression of c-Myc expression in mammary tumour cells.
Parajuli P; Tiwari RV; Sylvester PW
Cell Prolif; 2015 Aug; 48(4):421-35. PubMed ID: 26096843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]